Adoptive T-Cell Immunotherapy.

Epstein-Barr virus (EBV) contributes to diverse malignancies defined by distinct patterns of viral latent antigen expression, which shape tumor immunogenicity and influence responsiveness to T-cell therapies. Adoptive transfer of EBV-specific T cells (EBVSTs) has demonstrated exceptional efficacy in posttransplant lymphoproliferative disease (PTLD), particularly after hematopoietic stem cell transplantation (HSCT), when donor-derived EBVSTs restore antiviral immunity, persist long term, and induce high response rates with minimal toxicity. Advances in manufacturing and the development of multispecific virus-specific T cells (VSTs) have increased accessibility, while "off-the-shelf" third-party products now enable urgent treatment and have achieved regulatory approval in Europe. Type 2 latency tumors such as Hodgkin lymphoma, non-Hodgkin lymphoma, and nasopharyngeal carcinoma remain more challenging due to restricted antigen expression and immunosuppressive tumor microenvironments. Strategies that enrich T cells targeting the type 2 latency antigens, LMP1, LMP2, EBNA1, and BARF1 have improved outcomes, but many patients require enhanced approaches to overcome tumor immune evasion. Genetic engineering technologies-resistance to immunosuppressive drugs, providing cytokine support, dominant-negative TGFβ receptors, chemokine receptors, and chimeric antigen receptors-offer promising avenues to improve persistence, trafficking, and antitumor potency. Collectively, the clinical experience underscores the safety, durability, and therapeutic potential of EBVSTs across EBV-associated diseases. Continued innovation in engineering and antigen targeting is poised to broaden VST applicability and support development of widely available cell therapies for EBV-associated and other cancers.